[{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2020","type":"Not Applicable","leadProduct":"VTX-803","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Cell and Gene therapy","year":"2020","type":"Agreement","leadProduct":"VTX-801","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Vivet Therapeutics","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Vivet Therapeutics"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Mirum Pharmaceuticals","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Collaboration","leadProduct":"VTX-803","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Mirum Pharmaceuticals","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Mirum Pharmaceuticals"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Pfizer Inc","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2021","type":"Not Applicable","leadProduct":"VTX-801","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vivet Therapeutics \/ Pfizer","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Pfizer"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"French Government","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Funding","leadProduct":"VTX-806","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0.01,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0.01,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ French Government","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ French Government"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"VTX-801","moa":"","graph1":"Genetic Disease","graph2":"Phase I\/ Phase II","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"7","companyTruncated":"Vivet Therapeutics \/ Not Applicable"},{"orgOrder":0,"company":"Vivet Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"FRANCE","productType":"Cell and Gene therapy","year":"2024","type":"Not Applicable","leadProduct":"VTX-806","moa":"","graph1":"Genetic Disease","graph2":"Preclinical","graph3":"Vivet Therapeutics","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Vivet Therapeutics \/ Not Applicable","highestDevelopmentStatusID":"4","companyTruncated":"Vivet Therapeutics \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals by Vivet Therapeutics

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : VTX-806, an Adeno-associated viral (AAV) vector encoding human CYP27A1 is being investigating for the treatment of Cerebrotendinous Xanthomatosis (CTX).

                          Brand Name : VTX-806

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          September 05, 2024

                          Lead Product(s) : VTX-806

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          02

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : VTX-801 is a replication-deficient recombinant adeno-associated viral vector (rAAV) gene therapy, which is being evaluated for the treatment of wilson disease.

                          Brand Name : VTX-801

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          April 08, 2024

                          Lead Product(s) : VTX-801

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          03

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Vivet will use funds to develop VTX-806, aiming to halt or reverse disease progression in cerebrotendinous xanthomatosis patients.

                          Brand Name : VTX-806

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          February 01, 2024

                          Lead Product(s) : VTX-806

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : French Government

                          Deal Size : $5.2 million

                          Deal Type : Funding

                          blank

                          04

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : VTX-801 is a novel investigational gene therapy to be evaluated in a Phase 1/2 clinical trial to determine the safety, tolerability, and pharmacological activity of a single intravenous infusion in adult patients with Wilson Disease.

                          Brand Name : VTX-801

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          August 12, 2021

                          Lead Product(s) : VTX-801

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Sponsor : Pfizer Inc

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank

                          05

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Vivet will continue to advance the preclinical studies for VTX-803 and VTX-802 for PFIC3 and PFIC2. Mirum has the exclusive option to license the programs after which Mirum would lead the clinical development and any future commercialization of the progr...

                          Brand Name : VTX-803

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 12, 2021

                          Lead Product(s) : VTX-803

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Mirum Pharmaceuticals

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          06

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : Under the terms of the agreement, Pfizer will provide clinical supply for a Phase 1/2 clinical trial evaluating Vivet’s proprietary, investigational gene therapy, VTX-801, for the potential treatment of Wilson disease, a rare and potentially life-threa...

                          Brand Name : VTX-801

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 23, 2020

                          Lead Product(s) : VTX-801

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Phase I/ Phase II

                          Recipient : Pfizer Inc

                          Deal Size : Undisclosed

                          Deal Type : Agreement

                          blank

                          07

                          PharmaVenue
                          Not Confirmed
                          PharmaVenue
                          Not Confirmed

                          Details : VTX-803 is Vivet’s second gene therapy product to be granted Orphan Drug Designation. VTX-803 is currently under IND-enabling studies and initiation of clinical development is planned for the second part of 2021 in both the US and the EU.

                          Brand Name : Undisclosed

                          Molecule Type : Cell and Gene therapy

                          Upfront Cash : Not Applicable

                          June 01, 2020

                          Lead Product(s) : VTX-803

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Preclinical

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank